MODIFICATION
A -- 2018 NIAID Omnibus Broad Agency Announcement - Amendment 2 - Amendment 1
- Notice Date
- 7/3/2018
- Notice Type
- Modification/Amendment
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 5601 Fishers Lane, 3rd Floor, MSC 9821, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIAID-BAA2018
- Point of Contact
- Julie Catherine Rodriguez, Phone: 301-402-2284, George Kennedy, Phone: 240-669-5170
- E-Mail Address
-
julie.rodriguez@nih.gov, kennedyg@mail.nih.gov
(julie.rodriguez@nih.gov, kennedyg@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Attachment - HHS-NIH-NIAID-BAA2018 - Amendment 1 NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2018 1. This broad agency announcement (BAA) will be available ONLY via electronic means. Printed copies of the announcement will not be distributed. Potential offerors are encouraged to refer frequently to the GPE for updates on the program. Any updates or corrections to the announcement will be posted there. The BAA is governed by Federal Acquisition Regulation (FAR) 6.102(d)(2) and FAR 35.016, as well as the NIH Policy Manual, Manual Chapter 6035, Broad Agency Announcements. A BAA may be used as a solicitation mechanism for basic and applied research directed toward advancing the state-of-the-art or increasing knowledge or understanding and that part of development not related to the development of a specific system or hardware procurement. BAAs are general in nature, identifying areas of research interest, and shall only be used when meaningful proposals with varying technical/scientific approaches can be reasonably anticipated. Offers submitted in response to this BAA will be required to present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Statement of Work (SOW), including the specific technical requirements and performance specifications, shall be developed and proposed by the Offeror, not the Government. Proposals received in the response to this BAA are NOT evaluated against each other since they are not submitted in accordance with a common SOW issued by the Government. Instead, Research and Technical Objectives will be provided in the BAA that describe individual Research Areas in which the Government is interested. Proposals received in response to the BAA will be evaluated in accordance with the Evaluation Factors for Award specified in the announcement. The Government reserves the right to conduct discussions with all, some, one, or none of the proposals received in response to this BAA. If discussions are conducted, the Government reserves the right to suggest modifying, adding or deleting milestones, decision points, research plans, processes, schedules, budget or product. The Government also reserves the right to make awards without discussions. Additionally, the Government reserves the right to accept proposals in their entirety or to select only portions of proposals for award. Multiple awards are anticipated. Selection for award under this BAA will be based upon the evaluation factors, importance to the agency programs, and the availability of funds. 2. The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH. The Research Areas included in this NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2018, as well as the projected amounts of available funding, are discussed below. Dates for receipt of proposals are identified separately for EACH Research Area within the solicitation. DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID), NIAID, NIH NIAID estimates that two or more awards may be issued for the Research Areas identified below, for a total estimated funding amount up to $15.5 million for non-severable base contract work across all contracts (direct and indirect costs combined.) The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years. Research Area 001: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases The objective of this Research Area is the development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of select pathogens, or in response to naturally-occurring outbreaks of infectious diseases caused by pathogens identified in this Research Area. Solicited products are anticipated to include: Antibacterial Therapeutics; Antiviral Therapeutics; and, Anti-toxin Therapeutics. Research Area 002: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases The objective of this Research Area is the development of vaccines for scenarios associated with intentional release of a NIAID Category A, B, or C Priority Pathogen, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens or Zika virus (Zika virus vaccine would be included only as a component of a multivalent vaccine for other pathogens such as a vaccine for Flavivirus family). Solicited Products are anticipated to include: Technology Gaps that Slow Progression to Clinical Testing; Novel Vaccine "Plug-and-Play" Technologies; Enhanced Vaccine Performance (with special interest in simplicity and speed of delivery, rapid immune response and sterilizing immunity); and Vaccines Against Antimicrobial Resistance Threats. DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID), NIAID and DIVISION OF ALLERGY, IMMUNOLOGY, AND TRANSPLANTATION (DAIT), NIAID, NIH NIAID estimates that two or more awards may be issued for Research Area 003 Component A: Vaccine Center, for a total first year base cost (direct and indirect costs combined) of roughly $13 million each; one award may be issued for Research Area 003 Component B: Vaccine Manufacturing and Toxicology Core, for a total first year base cost of roughly $500,000; and one award may be issued for Research Area 003 Component C, Clinical Core, for a total first year base cost of roughly $1 million, depending on the number of technically meritorious proposals, importance to agency programs, and availability of funds. The total cost for each award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed seven (7) years. Awards are anticipated to be made in or around August 2019. Research Area 003 - Collaborative Influenza Vaccine Innovation Centers (CIVICs) The objective of Research Area 003 is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity ("universal influenza vaccines"). Research Area 003 will support iterative vaccine design based on detailed immunologic assessment of influenza vaccine candidates through pre-clinical animal studies, early phase clinical trials and healthy volunteer human challenge studies to advance the most promising vaccine candidates into Phase I/II clinical trials. The desired attributes of a universal influenza vaccine are that it: • Be at least 75% effective against symptomatic influenza virus infection. • Protect against group I and group II influenza A viruses (influenza B virus would be a secondary target). • Provide durable protection that lasts at least one year and preferably through multiple influenza seasons. • Be suitable for all age groups, recognizing that different vaccines may be needed to provide optimal protection in certain populations. NIAID will work with the Contractors to facilitate a CIVICs program that: • Is comprised of well-integrated, multi-disciplinary teams of investigators that work collaboratively across Centers and Cores to support the research objectives of this program as guided by NIAID. • Employs state-of-the-art, cutting-edge techniques and strategies, and bring in expertise from outside of the influenza field, to design innovative influenza vaccine approaches. • Employs an iterative process, based on principles of influenza immunity, to achieve the desired attributes of a universal influenza vaccine. • Works collaboratively to test novel combinations and conduct head-to-head comparisons of influenza vaccine approaches under development in order to identify, down-select and advance the most promising vaccine candidates. • Collaborates with and leverage other NIAID extramural and intramural research programs to contribute to the development of universal and improved seasonal influenza vaccines. 3. Any responsible offeror may submit a proposal which shall be considered by the Agency. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov/NIAID and then click on "How to Submit."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIAID/HHS-NIH-NIAID-BAA2018/listing.html)
- Record
- SN04978351-W 20180705/180703230930-8d93296f400f4e7b8b9c29d3204ed709 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |